149 related articles for article (PubMed ID: 28488104)
1. Health-Related Quality of Life in Patients with Hepatocellular Carcinoma Treated with Initial Transarterial Chemoembolization.
Hinrichs JB; Hasdemir DB; Nordlohne M; Schweitzer N; Wacker F; Vogel A; Kirstein MM; Marquardt S; Rodt T
Cardiovasc Intervent Radiol; 2017 Oct; 40(10):1559-1566. PubMed ID: 28488104
[TBL] [Abstract][Full Text] [Related]
2. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
[TBL] [Abstract][Full Text] [Related]
3. Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma.
Kirchner T; Marquardt S; Werncke T; Kirstein MM; Brunkhorst T; Wacker F; Vogel A; Rodt T
Abdom Radiol (NY); 2019 Apr; 44(4):1554-1561. PubMed ID: 30311050
[TBL] [Abstract][Full Text] [Related]
4. Quality of life in patients undergoing repetitive TACE for the treatment of intermediate stage HCC.
Hartrumpf KJ; Marquardt S; Werncke T; Murray T; Kirstein MM; Vogel A; Wacker F; Rodt T
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1991-1999. PubMed ID: 30008024
[TBL] [Abstract][Full Text] [Related]
5. Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data.
Li L; Mo FK; Chan SL; Hui EP; Tang NS; Koh J; Leung LK; Poon AN; Hui J; Chu CM; Lee KF; Ma BB; Lai PB; Chan AT; Yu SC; Yeo W
BMC Cancer; 2017 Jan; 17(1):8. PubMed ID: 28052758
[TBL] [Abstract][Full Text] [Related]
6. Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients.
Li L; Chan SL; Mo F; Hui EP; Koh J; Chan AK; Tang NL; Chu CM; Hui J; Lee KF; Yu S; Yeo W
Qual Life Res; 2019 Sep; 28(9):2597-2607. PubMed ID: 31037590
[TBL] [Abstract][Full Text] [Related]
7. Transarterial chemoembolization for hepatocellular carcinoma: quality of life, tumour response, safety and survival comparing two types of drug-eluting beads.
Grumme J; Werncke T; Meine TC; Becker LS; Kloeckner R; Maschke SK; Kirstein MM; Vogel A; Wacker FK; Meyer BC; Hinrichs JB; Rodt T
Abdom Radiol (NY); 2020 Oct; 45(10):3326-3336. PubMed ID: 31781900
[TBL] [Abstract][Full Text] [Related]
8. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma.
Kolligs FT; Bilbao JI; Jakobs T; Iñarrairaegui M; Nagel JM; Rodriguez M; Haug A; D'Avola D; op den Winkel M; Martinez-Cuesta A; Trumm C; Benito A; Tatsch K; Zech CJ; Hoffmann RT; Sangro B
Liver Int; 2015 Jun; 35(6):1715-21. PubMed ID: 25443863
[TBL] [Abstract][Full Text] [Related]
9. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma.
Hucke F; Pinter M; Graziadei I; Bota S; Vogel W; Müller C; Heinzl H; Waneck F; Trauner M; Peck-Radosavljevic M; Sieghart W
J Hepatol; 2014 Dec; 61(6):1287-96. PubMed ID: 25016222
[TBL] [Abstract][Full Text] [Related]
10. Transarterial Chemoembolization Monotherapy Versus Combined Transarterial Chemoembolization-Microwave Ablation Therapy for Hepatocellular Carcinoma Tumors ≤5 cm: A Propensity Analysis at a Single Center.
Chen QF; Jia ZY; Yang ZQ; Fan WL; Shi HB
Cardiovasc Intervent Radiol; 2017 Nov; 40(11):1748-1755. PubMed ID: 28681222
[TBL] [Abstract][Full Text] [Related]
11. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.
Heng-jun G; Yao-jun Z; Min-shan C; Mei-xian C; Jun-ting H; Li X; Lau WY
Liver Int; 2014 Apr; 34(4):612-20. PubMed ID: 24028297
[TBL] [Abstract][Full Text] [Related]
12. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: a propensity score analysis.
Hsu CY; Huang YH; Chiou YY; Su CW; Lin HC; Lee RC; Chiang JH; Huo TI; Lee FY; Lee SD
Liver Transpl; 2011 May; 17(5):556-66. PubMed ID: 21506244
[TBL] [Abstract][Full Text] [Related]
13. TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma.
Sciarra A; Ronot M; Di Tommaso L; Raschioni C; Castera L; Belghiti J; Bedossa P; Vilgrain V; Roncalli M; Paradis V
Liver Int; 2015 Nov; 35(11):2466-73. PubMed ID: 25865109
[TBL] [Abstract][Full Text] [Related]
14. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction.
Hsin IF; Hsu CY; Huang HC; Huang YH; Lin HC; Lee RC; Chiang JH; Lee FY; Huo TI; Lee SD
J Clin Gastroenterol; 2011 Jul; 45(6):556-62. PubMed ID: 21666547
[TBL] [Abstract][Full Text] [Related]
15. Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study.
Pinato DJ; Arizumi T; Jang JW; Allara E; Suppiah PI; Smirne C; Tait P; Pai M; Grossi G; Kim YW; Pirisi M; Kudo M; Sharma R
Oncotarget; 2016 Jul; 7(28):44705-44718. PubMed ID: 27244889
[TBL] [Abstract][Full Text] [Related]
16. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
17. Combination of radiofrequency ablation with transarterial chemoembolization for treatment of hepatocellular carcinoma: experience from a Danish tertiary liver center.
Bharadwaz A; Bak-Fredslund KP; Villadsen GE; Nielsen JE; Simonsen K; Sandahl TD; Grønbæk H; Nielsen DT
Acta Radiol; 2016 Jul; 57(7):844-51. PubMed ID: 26342009
[TBL] [Abstract][Full Text] [Related]
18. Chemoembolization Adopting Polyethylene Glycol Drug-Eluting Embolics Loaded With Doxorubicin for the Treatment of Hepatocellular Carcinoma.
Aliberti C; Carandina R; Sarti D; Mulazzani L; Pizzirani E; Guadagni S; Fiorentini G
AJR Am J Roentgenol; 2017 Aug; 209(2):430-434. PubMed ID: 28537756
[TBL] [Abstract][Full Text] [Related]
19. An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma.
Anota A; Boulin M; Dabakuyo-Yonli S; Hillon P; Cercueil JP; Minello A; Jouve JL; Paoletti X; Bedenne L; Guiu B; Bonnetain F
BMJ Open; 2016 Jun; 6(6):e010696. PubMed ID: 27342239
[TBL] [Abstract][Full Text] [Related]
20. [Single center experience over a 5-year period with sequential transarterial chemoembolization (TACE) in the treatment of hepatocellular carcinoma (HCC)].
Herber SC; Otto G; Woerns M; Moench C; Kanzler S; Junginger T; Schneider J; Schuchmann M; Kummer I; Manzl N; Düber C; Pitton MB
Rofo; 2007 Mar; 179(3):289-99. PubMed ID: 17325996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
